Publications
2025
CTLA-4 – two pathways to anti-tumour immunity?
Ward, F. J., Kennedy, P. T., Al-Fatyan, F., Dahal, L. N., & Abu Eid, R. (n.d.). CTLA-4 – two pathways to anti-tumour immunity?. Immunotherapy Advances. doi:10.1093/immadv/ltaf008
2024
Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.
Kennedy, P. T., Saulters, E. L., Duckworth, A. D., Lim, Y. J., Woolley, J. F., Slupsky, J. R., . . . Dahal, L. N. (2024). Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.. Molecular therapy : the journal of the American Society of Gene Therapy, 32(2), 457-468. doi:10.1016/j.ymthe.2023.11.028
Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers.
Saulters, E., Kennedy, P. T., Carter, R. J., Alsufyani, A., Jones, T. M., Woolley, J. F., & Dahal, L. N. (2024). Differential Regulation of the Stimulator of Interferon Genes pathway in Human Papillomavirus positive and negative Head and Neck Cancers.. Cancer research communications. doi:10.1158/2767-9764.crc-23-0299
2023
Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Kennedy, P. T., Zannoupa, D., Son, M. H., Dahal, L. N., & Woolley, J. F. (2023). Neuroblastoma: an ongoing cold front for cancer immunotherapy.. Journal for immunotherapy of cancer, 11(11), e007798. doi:10.1136/jitc-2023-007798
Soluble CTLA-4 raises the threshold for T-cell activation and modulates anti-tumour immunity
Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2023). Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers. doi:10.1158/0008-5472.c.6513438
Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects
2022
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms
Simpson, A. P., Roghanian, A., Oldham, R. J., Chan, H. T. C., Penfold, C. A., Kim, H. J., . . . Cragg, M. S. (2022). FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. CELL REPORTS, 40(3). doi:10.1016/j.celrep.2022.111099
Worked to the bone: antibody-based conditioning as the future of transplant biology
Griffin, J. M., Healy, F. M., Dahal, L. N., Floisand, Y., & Woolley, J. F. (2022). Worked to the bone: antibody-based conditioning as the future of transplant biology. JOURNAL OF HEMATOLOGY & ONCOLOGY, 15(1). doi:10.1186/s13045-022-01284-6
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy
Hussain, K., Liu, R., Smith, R. C. G., Muller, K. T. J., Ghorbani, M., Macari, S., . . . Cragg, M. S. (2022). HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 41(1). doi:10.1186/s13046-022-02294-5
TGF beta 2 Induces the Soluble Isoform of CTLA-4-Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
Khanolkar, R. C., Zhang, C., Al-Fatyan, F., Lawson, L., Depasquale, I., Meredith, F. M., . . . Ward, F. J. (2022). TGF beta 2 Induces the Soluble Isoform of CTLA-4-Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. FRONTIERS IN IMMUNOLOGY, 12. doi:10.3389/fimmu.2021.763877
2021
Recent Progress in Interferon Therapy for Myeloid Malignancies
Healy, F. M., Dahal, L. N., Jones, J. R. E., Floisand, Y., & Woolley, J. F. (2021). Recent Progress in Interferon Therapy for Myeloid Malignancies. FRONTIERS IN ONCOLOGY, 11. doi:10.3389/fonc.2021.769628
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Bloehdorn, J., Braun, A., Taylor-Weiner, A., Jebaraj, B. M. C., Robrecht, S., Krzykalla, J., . . . Mertens, D. (2021). Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-25403-y
STINGing Viral Tumors: What We Know from Head and Neck Cancers
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2021). STINGing Viral Tumors: What We Know from Head and Neck Cancers. CANCER RESEARCH, 81(15), 3945-3952. doi:10.1158/0008-5472.CAN-21-0785
Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia
Alsufyani, A., Alanazi, R., Woolley, J. F., & Dahal, L. N. (2021). Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia. MOLECULAR CANCER RESEARCH, 19(5), 753-756. doi:10.1158/1541-7786.MCR-20-0871
Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review
Wells, G., Kennedy, P. T., & Dahal, L. N. (n.d.). Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review. Frontiers in Immunology, 12. doi:10.3389/fimmu.2021.651687
2020
The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus
Dahal, L. N., Barker, R. N., & Ward, F. J. (2020). The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus. JOURNAL OF RHEUMATOLOGY, 47(2), 302-304. doi:10.3899/jrheum.190678
2019
Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia
Carter, M. J., Dahal, L. N., Cleary, K. L. S., Marshall, M. J. E., French, R. R., Beers, S. A., & Cragg, M. S. (2019). Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. In CHRONIC LYMPHOCYTIC LEUKEMIA (Vol. 1881, pp. 173-184). doi:10.1007/978-1-4939-8876-1_14
Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues
Sorrelle, N., Ganguly, D., Dominguez, A. T. A., Zhang, Y., Huang, H., Dahal, L. N., . . . Brekken, R. A. (2019). Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. JOURNAL OF IMMUNOLOGY, 202(1), 292-299. doi:10.4049/jimmunol.1800878
2018
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., . . . Beers, S. A. (2018). Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. IMMUNITY, 49(5), 958-970.e7. doi:10.1016/j.immuni.2018.09.014
Hiding in Plain Sight: Soluble Immunomodulatory Receptors
Dahal, L. N., Schwarz, H., & Ward, F. J. (2018). Hiding in Plain Sight: Soluble Immunomodulatory Receptors. TRENDS IN IMMUNOLOGY, 39(10), 771-774. doi:10.1016/j.it.2018.08.004
On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies
Ward, F. J., Dahal, L. N., & Abu-Eid, R. (2018). On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. FRONTIERS IN IMMUNOLOGY, 9, 12 pages. doi:10.3389/fimmu.2018.02182
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy
Dahal, L. N., Huang, C. -Y., Stopforth, R. J., Mead, A., Chan, K., Bowater, J. X., . . . Beers, S. A. (2018). Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. JOURNAL OF IMMUNOLOGY, 201(4), 1211-1221. doi:10.4049/jimmunol.1701122
UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion
Dahal, L. N., Gadd, A., Edwards, A. D., Cragg, M. S., & Beers, S. A. (2018). UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 87(6). doi:10.1111/sji.12666
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
Yu, X., Chan, H. T. C., Orr, C. M., Dadas, O., Booth, S. G., Dahal, L. N., . . . White, A. L. (2018). Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. CANCER CELL, 33(4), 664-675. doi:10.1016/j.ccell.2018.02.009
New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcRIIB (CD32B)
Roghanian, A., Stopforth, R. J., Dahal, L. N., & Cragg, M. S. (2018). New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcRIIB (CD32B). JOURNAL OF LEUKOCYTE BIOLOGY, 103(6), 1077-1088. doi:10.1002/JLB.2MIR0917-354R
2017
Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment
Turaj, A. H., Hussain, K., Cox, K. L., Rose-Zerilli, M. J. J., Testa, J., Dahal, L. N., . . . Lim, S. H. (2017). Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. CANCER CELL, 32(6), 777-791. doi:10.1016/j.ccell.2017.11.001
The dichotomy of T helper 17 cells in cancer
Dahal, L. N. (2017). The dichotomy of T helper 17 cells in cancer. NATURE REVIEWS IMMUNOLOGY, 17(9), 592-593. doi:10.1038/nri.2017.93
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy
Dahal, L. N., Dou, L., Hussain, K., Liu, R., Earley, A., Cox, K. L., . . . Beers, S. A. (2017). STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research, 77(13), 3619-3631. doi:10.1158/0008-5472.CAN-16-2784
TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter
Turaj, A. H., Dahal, L. N., Beers, S. A., Cragg, M. S., & Lim, S. H. (2017). TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter. CANCER RESEARCH, 77(12), 3376-3378. doi:10.1158/0008-5472.CAN-17-0412
PI3K delta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis
Carter, M. J., Cox, K. L., Blakemore, S. J., Turaj, A. H., Oldham, R. J., Dahal, L. N., . . . Cragg, M. S. (2017). PI3K delta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia, 31, 1423-1433. doi:10.1038/leu.2016.333
2016
PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis
Carter, M. J., Cox, K. L., Blakemore, S. J., Turaj, A. H., Oldham, R. J., Dahal, L. N., . . . Cragg, M. S. (2016). PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.3241.3241
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
Dahal, L. N., Basu, N., Youssef, H., Khanolkar, R. C., Barker, R. N., Erwig, L. P., & Ward, F. J. (2016). Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. ARTHRITIS RESEARCH & THERAPY, 18. doi:10.1186/s13075-016-1075-1
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?
Reddy, V., Dahal, L. N., Cragg, M. S., & Leandro, M. (2016). Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?. DRUG DISCOVERY TODAY, 21(8), 1330-1338. doi:10.1016/j.drudis.2016.06.009
2015
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors
Tutt, A. L., James, S., Laversin, S. A., Tipton, T. R. W., Ashton-Key, M., French, R. R., . . . Cragg, M. S. (2015). Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors. JOURNAL OF IMMUNOLOGY, 195(11), 5503-5516. doi:10.4049/jimmunol.1402988
FcγR requirements leading to successful immunotherapy
Dahal, L. N., Roghanian, A., Beers, S. A., & Cragg, M. S. (2015). FcγR requirements leading to successful immunotherapy. IMMUNOLOGICAL REVIEWS, 268(1), 104-122. doi:10.1111/imr.12342
Antagonistic Human FcϒRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
Roghanian, A., Teige, I., Martensson, L., Cox, K. L., Kovacek, M., Ljungars, A., . . . Cragg, M. S. (2015). Antagonistic Human FcϒRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. CANCER CELL, 27(04), 473-488. doi:10.1016/j.ccell.2015.03.005
Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
Tipton, T. R. W., Roghanian, A., Oldham, R. J., Carter, M. J., Cox, K. L., Mockridge, C. I., . . . Beers, S. A. (2015). Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. BLOOD, 125(12), 1901-1909. doi:10.1182/blood-2014-07-588376
Rehabilitation or the death penalty: Autoimmune B cells in the dock
Dahal, L. N., & Cragg, M. S. (2015). Rehabilitation or the death penalty: Autoimmune B cells in the dock. EUROPEAN JOURNAL OF IMMUNOLOGY, 45(3), 687-691. doi:10.1002/eji.201545464
2014
Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
Ward, F. J., Dahal, L. N., Khanolkar, R. C., Shankar, S. P., & Barker, R. N. (2014). Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?. IMMUNOTHERAPY, 6(10), 1073-1084. doi:10.2217/IMT.14.73
Isolation, Polarization, and Expansion of CD4<SUP>+</SUP> Helper T Cell Lines and Clones Using Magnetic Beads
Dahal, L. N., Barker, R. N., & Ward, F. J. (2014). Isolation, Polarization, and Expansion of CD4<SUP>+</SUP> Helper T Cell Lines and Clones Using Magnetic Beads. SYSTEMIC LUPUS ERYTHEMATOSUS: METHODS AND PROTOCOLS, 1134, 237-247. doi:10.1007/978-1-4939-0326-9_18
Optimising macrophage phenotype and function for anti-tumour immunity
Dahal, L. N., Earley, A. J., Murinello, S., Teeling, J. L., Duriez, P. J., Houghton, F. D., . . . Cragg, M. S. (2014). Optimising macrophage phenotype and function for anti-tumour immunity. In IMMUNOLOGY Vol. 143 (pp. 125-126). Retrieved from https://www.webofscience.com/
2013
Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia.
Dahal, L. N., Hall, L. S., Barker, R. N., & Ward, F. J. (2013). Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia.. Clinical and experimental immunology, 173(1), 58-66. doi:10.1111/cei.12091
The soluble isoform of CTLA-4 as a regulator of T-cell responses.
Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S. K., Kaewarpai, T., Xu, H., . . . Barker, R. N. (2013). The soluble isoform of CTLA-4 as a regulator of T-cell responses.. European journal of immunology, 43(5), 1274-1285. doi:10.1002/eji.201242529